EA201600457A1 - Фармацевтические композиции, содержащие диметилфумарат - Google Patents

Фармацевтические композиции, содержащие диметилфумарат

Info

Publication number
EA201600457A1
EA201600457A1 EA201600457A EA201600457A EA201600457A1 EA 201600457 A1 EA201600457 A1 EA 201600457A1 EA 201600457 A EA201600457 A EA 201600457A EA 201600457 A EA201600457 A EA 201600457A EA 201600457 A1 EA201600457 A1 EA 201600457A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical compositions
compositions containing
dimethyl fumarate
starch
containing dimethylfumarate
Prior art date
Application number
EA201600457A
Other languages
English (en)
Inventor
Мария Планельс-Хименес
Бегонья Дуарте-Лопес
Пере Гиро-Коль
Original Assignee
Альмираль, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49917530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201600457(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Альмираль, С.А. filed Critical Альмираль, С.А.
Publication of EA201600457A1 publication Critical patent/EA201600457A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В заявке описаны фармацевтические композиции, содержащие (а) диметилфумарат, (b) разбавитель, выбранный из группы, включающей моносахариды, дисахариды, крахмал и производные крахмала, неорганические соли кальция и магния, гидроксисахара и их смеси, (с) микрокристаллическую целлюлозу и (d) натриевую соль кроскармеллозы, в которых на диметилфумарат не нанесено устойчивое в желудке покрытие. Эти композиции предназначены для лечения некоторых воспалительных или аутоиммунных заболеваний или нарушений.
EA201600457A 2013-12-12 2014-12-05 Фармацевтические композиции, содержащие диметилфумарат EA201600457A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382504 2013-12-12
PCT/EP2014/076767 WO2015086467A1 (en) 2013-12-12 2014-12-05 Pharmaceutical compositions comprising dimethyl fumarate

Publications (1)

Publication Number Publication Date
EA201600457A1 true EA201600457A1 (ru) 2016-11-30

Family

ID=49917530

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201600457A EA201600457A1 (ru) 2013-12-12 2014-12-05 Фармацевтические композиции, содержащие диметилфумарат

Country Status (31)

Country Link
US (2) US20160310457A1 (ru)
EP (2) EP3656379A1 (ru)
JP (3) JP6581088B2 (ru)
KR (2) KR102353201B1 (ru)
CN (2) CN114159421B (ru)
AR (1) AR098746A1 (ru)
AU (2) AU2014363792B2 (ru)
BR (1) BR112016012179B1 (ru)
CA (2) CA3135273A1 (ru)
CL (1) CL2016001415A1 (ru)
CY (1) CY1124336T1 (ru)
DK (1) DK3079666T3 (ru)
EA (1) EA201600457A1 (ru)
ES (1) ES2860551T3 (ru)
HK (1) HK1224212A1 (ru)
HR (1) HRP20210468T1 (ru)
HU (1) HUE054408T2 (ru)
IL (2) IL287109B (ru)
LT (1) LT3079666T (ru)
MX (2) MX2016007105A (ru)
MY (1) MY179355A (ru)
NZ (2) NZ720287A (ru)
PH (2) PH12016501043B1 (ru)
PL (1) PL3079666T3 (ru)
PT (1) PT3079666T (ru)
RS (1) RS61658B1 (ru)
SG (3) SG10201802815UA (ru)
SI (1) SI3079666T1 (ru)
TW (2) TWI704915B (ru)
UA (2) UA120428C2 (ru)
WO (1) WO2015086467A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939990C (en) 2014-02-28 2018-07-10 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
AU2016273068A1 (en) 2015-06-01 2017-12-21 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
US10631564B2 (en) 2015-06-19 2020-04-28 University Of Southern California Enterically coated microparticle compositions and methods for modified nutrient delivery
US10744070B2 (en) 2015-06-19 2020-08-18 University Of Southern California Enteral fast access tract platform system
WO2017040272A1 (en) * 2015-08-31 2017-03-09 Banner Life Sciences Llc Fumarate ester dosage forms
CA3007483C (en) 2015-12-31 2021-12-07 Zaklady Farmaceutyczne Polpharma S.A. Process for preparation of an enteric coated granulate comprising dimethyl fumarate
WO2017129370A1 (en) * 2016-01-28 2017-08-03 Zaklady Farmaceutyczne Polpharma S.A. Process for preparation of a granulate comprising dimethyl fumarate
EP3413884A1 (en) * 2016-02-12 2018-12-19 Universität Zürich Dimethyl fumarate (dmf) for prevention or treatment of gout, acne, diabetes, vitiligo and/or pyoderma gangrenosum
WO2017145036A1 (en) * 2016-02-25 2017-08-31 Aurobindo Pharma Ltd Pharmaceutical compositions comprising dimethyl fumarate
KR20200018458A (ko) 2017-06-23 2020-02-19 알미랄, 에스.에이. 디메틸 푸마레이트를 포함하는 약학 조성물
JP7000148B2 (ja) * 2017-12-27 2022-01-19 日本化薬株式会社 ダサチニブを有効成分とする医薬組成物
WO2020053219A1 (en) 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
WO2020053218A1 (en) 2018-09-13 2020-03-19 Almirall, S.A. Treatment of psoriasis
KR102197465B1 (ko) * 2019-05-31 2020-12-31 주식회사 큐라클 디메틸푸마르산염을 함유한 장용성 정제
US20230055674A1 (en) * 2019-11-07 2023-02-23 Asahi Kasei Kabushiki Kaisha Cellulose composition and tablet
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
WO2022212893A1 (en) * 2021-04-02 2022-10-06 Biogen Ma Inc. Combination treatment methods of multiple sclerosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
CN101056624A (zh) * 2004-10-08 2007-10-17 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
LT2801354T (lt) 2004-10-08 2017-06-26 Forward Pharma A/S Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį
BRPI0610431A2 (pt) * 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, processo para preparar uma composição, cápsula, e, kit farmacêutico
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
JP2009510137A (ja) 2005-10-07 2009-03-12 アディテック・ファルマ・アクチボラゲット フマル酸エステルを含む制御放出医薬組成物
CN101304732A (zh) * 2005-10-07 2008-11-12 Adi技术制药股份公司 包含富马酸酯的控释药物组合物
WO2009118764A1 (en) * 2008-03-28 2009-10-01 Panacea Biotec Limited Pharmaceutical composition comprising diclofenac and paracetamol
US8906420B2 (en) 2009-01-09 2014-12-09 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
US20120034274A1 (en) 2009-01-09 2012-02-09 Forward Pharma A/S Pharmaceutical composition comprising one or more fumaric acid esters
EP3466420A1 (en) * 2009-04-29 2019-04-10 Biogen MA Inc. Dimethyl fumarate for the treatment of friedreich ataxia
RU2013154355A (ru) * 2011-06-03 2015-07-20 Ф. Хоффманн-Ля Рош Аг Способ лечения мезотелиомы ингибитором рi3к
RU2014125430A (ru) 2011-11-24 2015-12-27 Синтон Бв Контролируемое высвобождение частиц, содержащих диметилфумарат
CN104220061A (zh) * 2012-02-07 2014-12-17 比奥根艾迪克依蒙菲利亚公司 含有富马酸二甲酯的药物组合物

Also Published As

Publication number Publication date
TWI704915B (zh) 2020-09-21
PL3079666T3 (pl) 2021-09-06
PH12019502610A1 (en) 2021-02-22
KR20210150587A (ko) 2021-12-10
JP2016540003A (ja) 2016-12-22
JP6581088B2 (ja) 2019-09-25
US20160310457A1 (en) 2016-10-27
AU2019268075A1 (en) 2019-12-12
WO2015086467A1 (en) 2015-06-18
IL245685B (en) 2021-10-31
MX2020009745A (es) 2020-10-08
UA120428C2 (uk) 2019-12-10
TWI687218B (zh) 2020-03-11
IL245685A0 (en) 2016-06-30
KR102353201B1 (ko) 2022-01-18
BR112016012179A2 (ru) 2017-08-08
DK3079666T3 (da) 2021-03-22
PH12016501043A1 (en) 2016-07-04
CA2932054A1 (en) 2015-06-18
IL287109A (en) 2021-12-01
CA2932054C (en) 2022-09-20
TW201605435A (zh) 2016-02-16
SI3079666T1 (sl) 2021-04-30
EP3079666B1 (en) 2021-02-03
HUE054408T2 (hu) 2021-09-28
KR102335289B1 (ko) 2021-12-06
KR20160089397A (ko) 2016-07-27
US20210330628A1 (en) 2021-10-28
PH12016501043B1 (en) 2016-07-04
JP6945603B2 (ja) 2021-10-06
BR112016012179B1 (pt) 2023-04-18
HRP20210468T1 (hr) 2021-05-14
EP3079666A1 (en) 2016-10-19
AU2014363792A1 (en) 2016-06-09
LT3079666T (lt) 2021-03-25
MY179355A (en) 2020-11-05
EP3656379A1 (en) 2020-05-27
SG10201913076PA (en) 2020-02-27
TW202011953A (zh) 2020-04-01
UA123880C2 (uk) 2021-06-16
NZ720287A (en) 2020-05-29
HK1224212A1 (zh) 2017-08-18
AR098746A1 (es) 2016-06-08
CN105813634A (zh) 2016-07-27
AU2019268075B2 (en) 2020-12-17
SG10201913080VA (en) 2020-03-30
JP2021130689A (ja) 2021-09-09
MX2016007105A (es) 2016-08-11
CN114159421B (zh) 2023-08-25
SG10201802815UA (en) 2018-05-30
IL287109B (en) 2022-08-01
PT3079666T (pt) 2021-02-18
NZ759411A (en) 2020-06-26
JP2019218385A (ja) 2019-12-26
ES2860551T3 (es) 2021-10-05
CA3135273A1 (en) 2015-06-18
AU2014363792B2 (en) 2019-11-14
CN114159421A (zh) 2022-03-11
RS61658B1 (sr) 2021-04-29
CL2016001415A1 (es) 2017-01-20
CY1124336T1 (el) 2022-07-22

Similar Documents

Publication Publication Date Title
EA201600457A1 (ru) Фармацевтические композиции, содержащие диметилфумарат
EA201790785A1 (ru) Производные тетрагидроизохинолина
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201790740A1 (ru) Индолкарбоксамидные соединения
EA201590520A1 (ru) Фармацевтическая композиция с покрытием, содержащая регорафениб
EA201690952A1 (ru) Пиразол для лечения аутоиммунных расстройств
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
EA202090486A2 (ru) Соединения для лечения спинальной мышечной атрофии
JP2017506627A5 (ru)
EA201591531A1 (ru) Ингибиторы аргининметилтрансферазы и их применения
EA201690268A1 (ru) Замещенные производные хиназолин-4-она
EA201591491A1 (ru) Соединения тетрагидропирролотиазина
BR112016025356A2 (pt) 4-fenilpiperidinas substituido, sua preparação e utilização
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
CY1122352T1 (el) Φαρμακευτικη συνθεση περιεχοντας μιραβεγρονη
EA201892264A1 (ru) Производные тетрагидроизохинолина
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
EA201600434A1 (ru) Применение производных бензимидазолпролина
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201692270A1 (ru) Производные нафтиридиндиона
BR112015025058A8 (pt) Composição farmacêutica do tipo matriz contendo lacosamida
BR112019018028A2 (pt) Composto, combinação, e. uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BR112018012922A2 (pt) fórmula infantil que compreende peptídeos de leite humano
EA201692045A1 (ru) Производное фенантролинфосфоновой кислоты и способ его получения и применения
HRP20171514T1 (hr) Derivati indolouree supstituirani glukopiranozilom i njihova upotreba kao inhibitora sglt